Whether your personal interests are in supporting innovation, bringing lifesaving biomedical products to patients, training the next generation of biomedical leaders or fueling our economy, the Center for Biotechnology provides a vehicle to accomplish great things. Things that matter. Things that change, and save, lives.
Your involvement is an essential part of our future. Please consider a gift to the Center for Biotechnology which will help fuel innovation by ensuring that lifesaving technologies make it out of research labs and into the hands of patients.
Give to the Center for Biotechnology online through the Stony Brook Foundation. Contributions can be made to our Fund for Excellence. More information about donating through the Stony Brook Foundation can be found here.
Turning a good scientific idea into a successful biotech startup is a challenging journey.
What are the steps to building a successful biotech startup? How do startup founders find grants or investors to help them build their dreams?
This panel will highlight several successful programs that scientists can use when creating a successful biotech company. Learn what resources are available to turn your idea into a business and help you develop entrepreneurial skills.
The event will introduce funding and strategic programs available from IndieBio, the Center for Biotechnology, and SVB Startup Banking Life Sciences. Featuring Phuong Nguyen, Commercialization Fellow at the Center for Biotechnology; Stephen Chambers, Managing Director and Partner of IndieBio in New York and Anton Xavier, Director for Startup Life Science Banking in NY and the Northeast at SVB Financial Group.
The Center for Biotechnology is pleased to announce a request for proposals for our Research Evaluation and Commercialization Hub (REACH) award program. Awards will be in two categories: Feasibility ($50k/12mo) and Proof of Concept ($100K/12 mo.) Details on the full funding program overview and proposal guidelines can be found here.
The development of promising innovations often stalls due to limited early-stage funding to address translational uncertainties. The Center for Biotechnology's Research Evaluation and Commercialization Hub (REACH) award program bridges the translation gap between biomedical discovery and their development toward commercial goals. Program funding is intended to determine feasibility, develop proof-of-concept, and ultimately lead to follow-on funding, a strategic partnership, or company formation.
The REACH program supports faculty and postdoctoral researchers in translating bio-based, bio-convergence, and bio-medical research discoveries by providing targeted funding and strategic guidance to bridge the translation gap between discovery and development for commercialization.
[post_title] => Funding Opportunity: Research Evaluation and Commercialization Hub (REACH)Awards
[post_excerpt] => The Center for Biotechnology is pleased to announce a request for proposals for our REACH award program. Awards will be in two categories: Feasibility ($50k/12mo) and Proof of Concept ($100K/12 mo.)
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => news-reach25
[to_ping] =>
[pinged] =>
[post_modified] => 2025-03-24 12:11:36
[post_modified_gmt] => 2025-03-24 16:11:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4804
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[1] => WP_Post Object
(
[ID] => 4488
[post_author] => 4
[post_date] => 2024-10-24 10:45:00
[post_date_gmt] => 2024-10-24 14:45:00
[post_content] =>
Governor Kathy Hochul has unveiled plans for New York BioGenesis Park, a groundbreaking $430 million Cell and Gene Therapy (CGT) Innovation Hub in Nassau County, Long Island. To be developed by The Albanese Organization, Inc., this state-of-the-art facility would catalyze CGT research, development, clinical manufacturing, and commercialization across New York State. With a historic $150 million state investment—the largest nationwide for a cell and gene therapy hub—NYBGP would accelerate the delivery of new therapies from lab to patient in New York's diverse communities. This transformative hub aims to establish New York as the leading global destination for CGT innovation, driving economic growth, attracting top talent, and revolutionizing patient care statewide and beyond.
The Center for Biotechnology is thrilled to be counted as a partner in this effort, and is looking forward to working with our colleagues in the initiative to help catalyze and accelerate life-changing therapies.
New York BioGenesis Park is envisioned as a cutting-edge, full-service campus dedicated to advancing cell and gene therapies and accelerating their commercialization. At full build-out, the 700,000-square-foot park would create an end-to-end Cell and Gene Therapy innovation and supply center, featuring interconnected areas for public engagement, research, manufacturing, and collaboration.
A cornerstone of New York BioGenesis Park is its incubator, supported by a $50 million investment from ESD's Long Island Investment Fund. This facility will empower early-stage therapeutic developers by offering state-of-the-art wet lab space, shared equipment, office space, and other essential resources. This nurturing environment will provide Cell and Gene Therapy companies with access to specialized equipment, mentoring, and stage-appropriate financial guidance. As a critical component of New York BioGenesis Park, the incubator is poised to catalyze the growth of promising Cell and Gene Therapy companies by providing them with resources and support, unlocking their potential for innovation and success.
New York BioGenesis Park would foster strong ties with academic and medical institutions throughout New York, creating a robust ecosystem for Cell and Gene Therapy innovation. Collaborating with the Empire State Cellular Therapy Consortium and world-class institutions like Cold Spring Harbor Laboratory, the Feinstein Institutes, Northwell Health, Roswell Park, Stony Brook University, Weill Cornell, Columbia University and others around the state, New York BioGenesis Park would enhance research synergies and accelerate medical breakthroughs. This ecosystem would bring together experts in advanced Cell and Gene Therapy therapies, offering specialized facilities, services, and resources to both tenants and collaborating institutions. By facilitating cutting-edge science, innovative technology development and novel approaches to clinical trials, New York BioGenesis Park would ensure New York's institutions remain globally competitive in groundbreaking Cell and Gene Therapy research and commercialization.
[post_title] => Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park.
[post_excerpt] =>
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => long-island-to-be-location-for-nation-leading-cell-and-gene-therapy-innovation-hub-new-york-biogenesis-park
[to_ping] =>
[pinged] =>
[post_modified] => 2025-02-26 16:35:20
[post_modified_gmt] => 2025-02-26 21:35:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4488
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[2] => WP_Post Object
(
[ID] => 190
[post_author] => 1
[post_date] => 2013-07-12 13:19:13
[post_date_gmt] => 2013-07-12 13:19:13
[post_content] => Xiaflex, a drug developed, in part, with support by the Center for Biotechnology, has received a second approval for the treatment of men with Peyronie's disease, a painful curvature of the penis due to the buildup of plaque. The drug is already approved for the treatment of Depuytren's contracture, a condition that causes contraction of the fingers. Additional applications under development include frozen shoulder and cellulite. The drug is marketed by Auxilium. Read more here.
[post_title] => Advancing Ideas into Reality
[post_excerpt] => Candy that fights cavities. Vibrating away bone loss. A virtual colonoscopy. The Center for Biotechnology has helped accelerate the development of academic technologies into products that will benefit human health.
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => oldies-but-goodies
[to_ping] =>
[pinged] =>
[post_modified] => 2014-09-02 18:44:48
[post_modified_gmt] => 2014-09-02 18:44:48
[post_content_filtered] =>
[post_parent] => 0
[guid] => http://centerforbiotechnology.org/new/?p=190
[menu_order] => 231
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[3] => WP_Post Object
(
[ID] => 4426
[post_author] => 4
[post_date] => 2024-05-21 14:27:18
[post_date_gmt] => 2024-05-21 18:27:18
[post_content] =>
The Life Sciences Innovation and Entrepreneurship (LiSIE) program at Stony Brook is looking to give students a jump-start in the bioscience industry. The program is a joint effort between the Department of Biomedical Engineering in the College of Engineering and Applied Sciences, the College of Business and the Center for Biotechnology. “From the lab to leadership”, the program aims to teach key business principles to life sciences students so they’re equipped to work in the business side of science.
Read the recent SBU News feature on the program and the CFB Appointed Director Director of the Program in Life Sciences Innovation and Entrepreneurship, Dr. Louis A. Peña.
[post_title] => Fueling BioEntrepreneurship at Stony Brook University
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fueling-bioentrepreneurship-at-stony-brook-university
[to_ping] =>
[pinged] =>
[post_modified] => 2025-02-24 12:43:53
[post_modified_gmt] => 2025-02-24 17:43:53
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4426
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[4] => WP_Post Object
(
[ID] => 2436
[post_author] => 4
[post_date] => 2016-10-24 13:50:10
[post_date_gmt] => 2016-10-24 13:50:10
[post_content] => The Life Sciences Summit is an early stage investor and business development conference that highlights innovation. On November 2-3, 2016, emerging biotech companies and academic innovators will convene in New York City to connect with investors and strategic partners with the goal of moving new discoveries through clinical development. The two-day program features corporate presentations by promising young companies with transformative science that targets unmet medical needs. It also features informative plenary sessions, business workshops, and therapeutic sessions.
There is still time to register and participate in this innovative conference that provides attendee the opportunity to networking with potential investors and strategic partners. REGISTER TODAY!
[post_title] => Life Sciences Summit 2016: November 2-3, NYC
[post_excerpt] => Don't Miss the Life Sciences Summit 2016! Organized by the Center for Biotechnology and Demy-Colton, the Summit is an early stage investor and business development conference that highlights innovation. The objective of the event is to connect emerging biotech companies and academic innovators with the capital and strategic partners they will need to move new discoveries through clinical development.
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => life-sciences-summit-2016-november-2-3-nyc
[to_ping] =>
[pinged] =>
[post_modified] => 2016-12-22 17:28:08
[post_modified_gmt] => 2016-12-22 17:28:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => http://centerforbiotechnology.org/?p=2436
[menu_order] => 163
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
)
[post_count] => 5
[current_post] => -1
[before_loop] => 1
[in_the_loop] =>
[post] => WP_Post Object
(
[ID] => 4804
[post_author] => 4
[post_date] => 2025-03-20 12:10:54
[post_date_gmt] => 2025-03-20 16:10:54
[post_content] =>
The Center for Biotechnology is pleased to announce a request for proposals for our Research Evaluation and Commercialization Hub (REACH) award program. Awards will be in two categories: Feasibility ($50k/12mo) and Proof of Concept ($100K/12 mo.) Details on the full funding program overview and proposal guidelines can be found here.
The development of promising innovations often stalls due to limited early-stage funding to address translational uncertainties. The Center for Biotechnology's Research Evaluation and Commercialization Hub (REACH) award program bridges the translation gap between biomedical discovery and their development toward commercial goals. Program funding is intended to determine feasibility, develop proof-of-concept, and ultimately lead to follow-on funding, a strategic partnership, or company formation.
The REACH program supports faculty and postdoctoral researchers in translating bio-based, bio-convergence, and bio-medical research discoveries by providing targeted funding and strategic guidance to bridge the translation gap between discovery and development for commercialization.
